taiba Make Strategic Investment in Immuneel Therapeutics to advance CAR T-cell Research and Make Therapies More Affordable.
July 30 2024 - 9:31AM
Business Wire
Further establishes taiba as a leading rare
disease and Hemato-oncology company poised to accelerate the next
generation of breakthrough treatments for people with unmet medical
needs and cancer.
In a significant move aimed at providing new hope to blood
cancer patients, taiba has announced a strategic investment in
Immuneel Therapeutics for $12 million. This strategic investment is
intended to advance CAR T-cell research, with a particular focus on
making CAR-T cell therapy commercially available at affordable
prices and developing the first Phase 2 trial for CD19 CAR-T
(IMN-003A) targeting B-cell malignancies, including leukemia and
lymphoma.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240730522797/en/
Dr Saif Alhasani, CEO of taiba Healthcare
Group (Photo: AETOSWire)
CAR (Chimeric Antigen Receptor) T-cell therapy is a cutting-edge
treatment pioneered in the United States, primarily used to treat
blood cancers. Over the past few years, CAR-T therapies have seen
significant growth, and the Indian CAR-T therapy is estimated to
cost about one-tenth of comparable commercial products available
globally.
“Our aim at taiba is to facilitate access to innovative
medicines within developing countries, particularly in the Middle
East and Africa. We achieve this through various approaches,
including in-licensing such medicines and supporting new treatments
within our region. Our focus remains on research and development,
especially in the fields of cell and gene therapies.” Said Dr Saif
Alhasani, CEO of taiba Healthcare Group.
About taiba
taiba Healthcare Group is based in Muscat, Oman, with regional
offices throughout the MENA region. Established 40 years ago, taiba
is committed to helping Rare disease patients across the GCC and
beyond, within the Middle East and Africa. The group operates
multiple subsidiaries, including pharmacies and multinational
pharmaceutical distribution, and has recently launched Menagen, a
state-of-the-art manufacturing facility focused on producing and
commercializing niche innovative and hard-to-make medications.
About Immuneel
Immuneel Therapeutics, established in 2018 by Biocon founder
Kiran Mazumdar-Shaw, Pulitzer Prize winner Siddhartha Mukherjee,
and Kush Parker, is a biotechnology company specializing in gene
therapies.
This investment by taiba marks a significant step forward in its
mission to develop and make accessible ground breaking treatments
for cancer patients.
Source: AETOSWire
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730522797/en/
Sultan Alhasani sultan@taibahealthcare.com